Entering text into the input field will update the search result below

CRXM Gene Biotherapeutics, Inc.
Stock Price & Overview

$0.00010.00 (0.00%)10:38 AM 11/22/23
Expert Market | $USD | Market Close


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Gene Biotherapeutics, Inc. logo
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
  • 11230 Sorrento Valley Road
  • Suite 220
  • San Diego, CA, 92121
  • United States
Phone Number
858 414 1477
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.